Core Scientific (CORZ) Cash from Financing Activities (2021 - 2026)

Core Scientific has reported Cash from Financing Activities for 6 years, with the latest figure at $2.2 billion in Q2 2026.

• Quarterly Cash from Financing Activities rose 7089.09% year-over-year to $2.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.2 billion (up 325.14% YoY) and the FY2025 annual result came in at -$63.1 million, down 107.7% from the prior year.
• Cash from Financing Activities advanced to $2.2 billion in Q2 2026 per CORZ's latest filing, from $971.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $2.2 billion in Q2 2026 and troughed at -$45.1 million in Q3 2022.
• A 5-year average of $233.9 million and a median of -$2.6 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities sank 148.04% in 2023, then soared 23239.16% in 2026.
• Over 5 years, Cash from Financing Activities stood at $38.1 million in 2022, then tumbled by 148.04% to -$18.3 million in 2023, then soared by 3369.23% to $598.2 million in 2024, then plunged by 103.65% to -$21.8 million in 2025, then jumped by 10282.38% to $2.2 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.2 billion, $971.4 million, and -$21.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.